Drug intelligence / Profile preview

DC1

Development stage: Phase 2
Modality: Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Inguinal Lymph Node Administration

Overview

DC1 is a HER-2-pulsed dendritic cell vaccine being investigated in a multicenter phase II study for the prevention of recurrence in patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant therapy. The vaccine aims to induce anti-tumor immunity by correcting low or absent anti-HER-2 CD4 Th1 responses. It is administered via US-guided inguinal lymph node injection. Initial safety results indicate it is well tolerated without significant toxicities.

Other names: HER-2-pulsed dendritic cell vaccineHER2-pulsed dendritic cell vaccineHER 2-pulsed dendritic cell vaccine

Beyond the preview

Go deeper on DC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC1.

Explore the full profile